Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5887 clinical trials
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

Accepts healthy volunteers
  • 0 views
  • 05 May, 2025
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.

ejection fraction
solid neoplasm
measurable disease
  • 0 views
  • 19 Feb, 2024
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

T lymphocytes can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.

aptt
pulse oximetry
lymphoma
apheresis
flow cytometry
  • 0 views
  • 19 Feb, 2024
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) in cancer patients. The main purpose of this study is to evaluate the efficacy and safety of nicotinic acid in solid tumor patients with grade II/III VEGFRi-associated HFSR.

  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

atezolizumab
hepatitis
immunomodulators
ct scan
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Tissue Retractors for Radiation Therapy of Head and Neck Tumors

The rate of therapy-associated side effects during and after radiotherapy of head and neck tumors is essential. The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D …

head and neck neoplasms
dental caries
neck tumor
head and neck cancer
tumour resection
  • 0 views
  • 19 Feb, 2024
Transcutaneous Breast Cancer Diagnosis by Canine Odorology

Patient with an indication of interventional percutaneous procedure for characterization of a breast lesion, palpable or not, classified as category 4 or 5, according to the Breast Imaging (BI) Report and Data System of the American College of Radiology (RADS) classification detected at mammography and/or breast ultrasound examination.

carcinoma
cancer diagnosis
fever
breast carcinoma
ultrasound breast
  • 0 views
  • 19 Feb, 2024
"CHOiCE"! Choose Health: Oncological Patients Cenetered Exercise

The program considers the preferences of EX of cancer survivors, giving the possibility to choose the EX modality (autonomous, with personal trainer or group class).

  • 0 views
  • 19 Feb, 2024
Liquid Biopsies and Imaging in Breast Cancer

The aim of the study is to show proof of concept for combining multi-parametric MRI with liquid biopsies in addition to conventional clinical and pathologic information, to accurately predict response to neoadjuvant treatment for patients with primary breast cancer.

breast carcinoma
carcinoma
adjuvant therapy
invasive breast cancer
pertuzumab
  • 0 views
  • 19 Feb, 2024
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

conjugated bilirubin
plasma oestradiol
tamoxifen
growth factor
anticoagulant therapy
  • 0 views
  • 19 Feb, 2024